Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies

@article{Moorkens2016OvercomingBT,
  title={Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies},
  author={Evelien Moorkens and Clara Jonker-Exler and I. Huys and Paul J Declerck and S. Simoens and A. Vulto},
  journal={Frontiers in Pharmacology},
  year={2016},
  volume={7}
}
  • Evelien Moorkens, Clara Jonker-Exler, +3 authors A. Vulto
  • Published 2016
  • Medicine
  • Frontiers in Pharmacology
  • Background: In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain healthcare expenses, biosimilars could be instrumental in reducing costs for medication and increasing patient access to treatment. Objectives: The aim of this study is to identify and describe the… CONTINUE READING
    Improving Access to Cancer Treatments: The Role of Biosimilars
    • 24
    • Open Access
    Biosimilars are coming: ready or not
    • 6
    Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
    • 11
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 87 REFERENCES
    The economics of biosimilars.
    • 159
    Biosimilars: what clinicians should know.
    • 276
    • Open Access
    Biosimilar therapeutics—what do we need to consider?
    • 197
    • Open Access
    Biosimilars: the science of extrapolation.
    • 216
    • Open Access
    A European perspective on the market accessibility of biosimilars
    • 36
    • Open Access
    Clinical considerations for biosimilar antibodies
    • 37
    • Open Access
    Risk management of biosimilars in oncology: each medicine is a work in progress
    • 17
    • Open Access
    Market entry of biosimilar monoclonal antibodies
    • 3
    How to select a biosimilar
    • 11